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INTRODUCTION 
 
 
Rapid diagnosis of hypertension can help prevent 
serious complications such as intracranial bleeding and 
heart failure. Identification of the intake of these 
substances may be important because their elimination 
can obviate the need for unnecessary, costly, and 
potentially dangerous evaluations, treatments, or both.1 
Drugs are often overlooked either as a cause of 
hypertension or as a cause of BP destabilization. 
Therefore, it is necessary to pay attention to the 
patient's pharmacological medical history, identify 
possible drug causes and subsequently evaluate the 
relevance of the adverse events. Drug related elevation 
of blood pressure can be caused by various mechanisms 
including increased intravascular volume due to 
inadequate hydration or fluid retention, direct or 
indirect activation of the sympathetic nervous system, 
direct vascular influence - vasoconstriction.2 
 
Drugs that can increase BP include antidepressants, 
glucocorticoids, thyroid hormones, 
immunosuppressants, or drugs that lead to 
mineralocorticoid excess by their mechanism, non-
steroidal anti-inflammatory drugs and sex hormones. 
Special attention should also be paid to blood pressure 
elevations during treatment with angiogenesis 
inhibitors in cancer patients.3 
 
 
 
 
 
ANTI-DEPRESSANT DRUGS 
The    effect  on   blood    pressure   depends  on   which  
mediators and receptors are affected by the 
antidepressant and the dose of administered drug. 
Blood pressure elevation is probably caused by their 
noradrenergic effect.2 Tricyclic antidepressants can 
result in hypertension by affecting noradrenaline and 
serotonin reuptake, and have other effects such as 
anticholinergic, antihistamine and alpha-1 lytic, which 
modulate the overall impact on the cardiovascular 
system and on the resulting blood pressure. The 
magnitude of the antidepressant dose administered is 
important in assessing the association of hypertension 
with the medication. For amitriptyline, dosulepine, 
clomipramine and maprotiline hypertension is not 
reported as an adverse reaction at all, for nortriptyline, 
the incidence rate of hypertension is reported as an 
uncommon adverse side effect, and for imipramine, the 
incidence rate of hypertension is reported as very rare.4  
 
The risk of BP elevation and tachycardia when 
mirtazapine is administered is very low; the probability 
of occurrence lower than 50% compared to tricyclic 
antidepressants is stated.5 High doses of venlafaxine 
cause hypertension in more than 12% of patients. A 
meta-analysis  has    shown     that    BP  increase is more  
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pronounced in the elderly and in male patients and is 
dose dependent.5 The incidence of elevated diastolic BP 
> 90 mmHg was statistically and clinically significant 
only at doses above 300 mg of venlafaxine per day.6 
 
ANTINEOPLASTIC AGENTS 
Hypertension is a common side effect that occurs 
during treatment with agents blocking the vascular 
endothelial growth factor pathway. These include 
monoclonal antibodies and tyrosine kinase inhibitors. 
Binding of VEGF to the respective receptor leads to 
activation of tyrosine kinase. VEGFR1 and VEGFR2 are 
mainly localized in endothelial cells. Activation of 
VEGFR2 triggers regulatory pathways necessary for 
endothelial biology. The stimulation of phospholipase 
C and its associated cascades, which play an important 
role in cell growth and differentiation, represent the 
first pathway. The second route leads to activation of 
phosphatidylinositol-3 kinase - protein kinase B, 
phosphorylation of endothelial nitric oxide synthase, 
increased production of nitric oxide and subsequent 
vasodilation. Third, VEGFR2-mediated activation of 
cyclooxygenase stimulates the production of 
vasodilatory prostacyclin.7,8 Another route involving 
cytoplasmic tyrosine kinases influences adhesion and 
permeability. VEGF also inhibits endothelial 
production of potent vasoconstrictor endothelin1. 
VEGF physiological signalling VEGFR2 maintains 
vascular tone by balancing NO and prostacyclin 
induced vasodilation and ET1 regulated 
vasoconstriction. In connection with the foregoing, 
agents that block the VEGF pathway may lead to 
hypertension or BP destabilization. Functional and 
structural changes in the vascular area are likely 
mechanisms of hypertension development. 
Vasoconstriction is enhanced by a decrease in NO and 
prostacyclin production and an increase in endothelin1 
production.9 
 
Renal dysfunction is not the initial cause of 
hypertension in patients treated with VEGF inhibitors, 
but inhibition of renal NOS associated with impaired 
sodium excretion followed by fluid retention may 
contribute to the development of hypertension.7,8,10 
Blood pressure elevation is rapid in most patients; 
blood pressure should be monitored closely especially 
during the first 3-4 weeks after initial drug 
administration and resolves after withdrawal. In 
patients with advanced cancer, elevated BP was 
detected with sorafenib therapy on the first day of 
treatment and fully expressed at the time when 
balanced drug concentrations were reached around day 
7.11 Not only do patients face the risk of developing 
hypertension when starting treatment with VEGF 
pathway inhibitors but they are also at risk of 
developing hypotension upon withdrawal. Patients 
receiving therapy with VEGF-blocking drugs are often 
polymorbid and have an extensive cardiological history 
and medication. In all patients on a VEGF-blocking 
medication, newly introduced medication should be 
considered as a possible cause of hypertension in the 
differential diagnosis of sudden BP destabilization, the 
severity of the adverse side effect should be evaluated, 
and the relevant course of action should be followed 
accordingly.12  
 
GLUCOCORTICOIDS 
The incidence of hypertension in patients with 
Cushing's syndrome is 70-80%, but only 15-20% in 
patients treated with high doses of synthetic 
corticosteroids that have lower mineralocorticoid 
activity than cortisol.13 Oxidative stress and nitric oxide 
deficiency may be involved in the pathogenesis of 
glucocorticoid-induced hypertension.14 However, the 
exact mechanism of glucocorticoid-induced 
hypertension is still not fully elucidated and appears to 
be multifactorial. 
 
IMMUNOSUPPRESSANTS 
The incidence of hypertension in cyclosporine therapy 
is 50% and 35% for tacrolimus.5 Everolimus and 
temsirolimus have antiproliferative effects which are 
used not only in transplantology to reduce lymphocyte 
proliferation, but also in oncology to influence tumor 
cell proliferation. The incidence of hypertension in both 
drugs has been reported in studies from 1 to 10%.15 The 
mechanism of pressure elevation includes changes in 
the level of vascular endothelial function, decreased 
levels of vasodilatory mediators (prostacyclin and nitric 
oxide), increased levels of vasoconstrictive endothelin 
and increased insulin resistance. 
 
ERYTHROPOIETIN 
Hypertension may develop in 20-30% of patients 
receiving erythropoietin, occurring 2 weeks to 4 months 
after initiation of treatment. The anticipated 
mechanism of this side effect is not exactly known, with 
increased calcium in vascular smooth muscle cells, 
activation of the local renin angiotensin aldosterone 
system, increased ET1 production and reduced NO 
synthesis playing a certain role (2). Erythropoietin may 
increase BP by more than 10 mmHg, more often in 
patients on dialysis than in patients not yet on dialysis.2 
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DRUGS AFFECTING THE EFFECT OF 
MINERALOCORTICOIDS 
Drugs interfering with corticoid metabolism by 
influencing the activity of some important enzymes 
may contribute to hypertension. The antifungal agent 
posaconazole may lead to an excess of 
mineralocorticoids in the body by its mechanism of 
action.16 Also, abiraterone, which is administered to 
patients with castration-resistant prostate cancer, leads 
to clinically significant corticoid imbalance in the body, 
cortisol deficiency, and an excess of 
mineralocorticoids.17  
 
NSAIDS 
A meta-analysis conducted in the 1990s showed that 
non-steroidal anti-inflammatory drugs (NSAIDs) used 
more than 1 week in uncomplicated hypertensive and 
normotensive patients increased BP by an average of 5 
mmHg.2 The exact mechanism by which NSAIDs 
contribute to BP elevation is not fully understood and 
is multifactorial. NSAIDs inhibit cyclooxygenase 1 and 
2, thus reducing prostaglandin synthesis, reducing NO 
and increasing ET1. NSAIDs reduce the efficacy of some 
antihypertensive drugs such as diuretics, betablockers 
and ACE inhibitors, but do not interfere with the action 
of calcium antagonists and centrally acting 
antihypertensive drugs.18 
 
SEX HORMONES 
Hypertension is 2-3 times more common in women 
using oral contraceptives than in the control group.19 
Estrogens and progestins are believed to increase the 
synthesis of angiotensinogen in the liver, thereby 
increasing the production of angiotensin II and the 
secretion of aldosterone, which activates the 
mineralocorticoid receptor and causes sodium 
resorption and water retention. Testosterone causes 
increased sodium and water retention through 
androgen receptor agonism.2 
 
CONCLUSION 
With exponential growth in pharmaceutical industry, 
several drugs which are generally perceived as a 
potential cause of hypertension development are now 
being used for prophylactic and therapeutic use across 
the globe. New salts that interfere with the 
pharmacodynamic effect of the body's regulatory 
mechanisms are already in the market and attention 
should be paid to this issue. Most patients with high 
blood pressure have essential hypertension or well-
known forms of secondary hypertension such as renal 
parenchymal disease, renal artery stenosis, 
hyperaldosteronism, or pheochromocytoma. 
Healthcare professionals are not too aware of drug 
associated increase in blood pressure. An accurate and 
detailed medical history detailing all medications being 
taken by the patient concomitantly or in past would 
help to identify the culprit drug in case of drug related 
hypertension. Identification of the intake of these 
substances may be important because their elimination 
can prevent the need for unnecessary, costly, and 
potentially dangerous evaluations, treatments, or both. 
 
REFERENCES 
1. Elliott WJ. Drug interactions and drugs that affect 
blood pressure. J Clin Hypertens (Greenwich). 
2006;8(10):731-7. 
2. Lovell AR, Ernst ME. Drug‑Induced Hypertension: 
Focus on Mechanisms and Management. Curr 
Hypertens Rep. 2017; 19:39. 
3. Salvetti M, Paini A, Bertacchini F, Stassaldi D, 
Aggiusti C, Agabiti Rosei C, et al. Acute blood pressure 
elevation: Therapeutic approach. Pharmacological 
Research.2018; 130:180–90. 
4. Scalco AZ, Scalco MZ, Azul JB, Lotufo Neto F. 
Hypertension and depression. Clinics 2005;60(3):241-
50. 
5. Sander GE. Secondary hypertension Drugs and herbal 
preparations that increase pressure. Journal of the 
American Society of Hypertension. 2014; 8(12):946–8. 
6. Thase ME. Effects of venlafaxine on blood pressure: a 
meta‑analysis of original data from 3744 depressed 
patients. J Clin Psychiatry 1998; 59(10): 502–508. 
7. Touyz RM, Lang NN, Herrmann J, van den Meiracker 
AH, Danser AHJ. Recent Advances in Hypertension and 
Cardiovascular toxicities with VEGF Inhibition. 
Hypertension. 2017; 70:220–6. 
8. Touyz RM, Herrmann SMS, Herrmann J. Vascular 
toxicities with VEGF inhibitor therapies–focus on 
hypertension and arterial thrombotic events. Journal of 
the American Society of Hypertension. 2018; 12(6): 409-
25. 
9. Agarwal M, Thareja N, Benjamin M, Akhondi A, 
Mitchell GD. Tyrosine Kinase Inhibitor‑Induced 
Hypertension. Curr Oncol Rep. 2018; 20(8):65. 
10. Hayman SR, Leung N, et al. VEGF Inhibition, 
Hypertension, and Renal Toxicity Curr Oncol Rep. 2012 
August; 14(4): 285–294. 
11. Maitland, ML, Kasza KL, et al. Ambulatory 
monitoring detects sorafenib‑induced blood pressure 
elevations on the first day of treatment. Clin Cancer 
Res. 2009; 15(19): 6250–6257. 
12. Colevas AD, Setser A. The NCI Common 
Terminology Criteria for Adverse Events (CTCAE) v 3.0 
378 
  International Healthcare Research Journal 2020;3(12):376-379.  
Drug Related Hypertension: A Review                                                                                                                                   Marya K et al.  
is the new standard for oncology clinical trials. Journal 
of Clinical Oncology. 2004;22(14_suppl): 6098−6098. 
13. Isidori AM, Graziadio C, Paragliola RM, Cozzolino A, 
Ambrogio AG, Colao A, et al. The hypertension of 
Cushing’s syndrome: controversies in the 
pathophysiology and focus on cardiovascular 
complications. Journal of Hypertension. 2015; 33: 44–60. 
14. Hattori T, Murase T, Erika Iwase, Keiji Takahashi, 
Masafumi Ohtake, Koji Tsuboi, et al. 
Glucocorticoid‑induced hypertension and cardiac 
injury: effects of mineralocorticoid and glucocorticoid 
receptor antagonism. Nagoya J. Med. Sci.2013; 75: 81−92. 
15. Eisen T, Sternberg CN, Robert C, Mulders P, Pyle L, 
Zbinden S, et al. Targeted Therapies for Renal Cell 
Carcinoma: Review of Adverse Event Management 
Strategies. J Natl Cancer Inst 2012; 104: 93–113.
16. Boughton Ch, Taylor D, et al. Mineralocorticoid 
hypertension and hypokalaemia induced by 
posaconazole. Endocrinol Diabetes Metab Case Rep. 
2018; 17–0157. 
17. Auchusa RJ, Yub MK, et al. Use of Prednisone With 
Abiraterone Acetate in Metastatic castration‑Resistant 
Prostate Cancer. The Oncologist 2014; 19: 1231–1240. 
18. Grossman A, Messerli FH, et al. Drug induced 
hypertension – An unappreciated cause of secondary 
hypertension. European Journal of Pharmacology. 2015; 
763: 15–22. 
19. Gyamlani G, Gerac SA. Secondary Hypertension due 
to Drugs and Toxins. Southern Medical Journal. 2007; 
7(100): 692−9. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
AUTHOR AFFILIATIONS: (*Corresponding Author) 
1. MBBS, Consultant Physician 
Elegance Skin Clinic, Alpha 1, Greater Noida 201306 
 
Source of support: Nil, Conflict of interest: None declared 
Cite this article as: 
Marya K, Nagar S, Sharma K. Drug Related Hypertension: A Review on an 
Unappreciated Cause of Blood Pressure Increase. Int Healthc Res J. 
2020;3(12):376-379. https://doi.org/10.26440/IHRJ/0312.03196 
Contact corresponding author at: marya.k[at]eleganceclinic[dot]com 
379 
